Asthma Crisis in New York: Rising Costs and Disparities Threaten Public Health
As autumn descends, New York faces a predictable yet increasingly urgent public health challenge: a surge in asthma-related hospitalizations. The convergence of peak allergy season, the return to school, and the onset of flu season creates a perfect storm for those living with this chronic respiratory condition. However, a less visible, yet equally dangerous, factor is exacerbating the crisis – the soaring cost of essential asthma medication.
The Rising Tide of Asthma in the Empire State
Asthma affects over 1.4 million adults and an estimated 315,000 children in New York State, according to data from the New York State Department of Health and the Centers for Disease Control and Prevention (2021 figures). While asthma is a manageable condition with proper care, access to that care is increasingly hampered by financial barriers. The price of life-sustaining inhalers has skyrocketed in recent years, reaching as high as $645 per month, as reported by the Senate Committee on Health, Education, Labor and Pensions (HELP).
This exorbitant cost forces difficult choices. Many individuals are compelled to ration their medication, skipping doses or abandoning treatment altogether – a dangerous gamble that can lead to preventable hospitalizations and, tragically, even death. Even those with health insurance find themselves burdened by deductibles and copayments, making consistent access to inhalers a significant financial strain.
Disparities in Asthma Care: A Matter of Equity
The burden of asthma is not shared equally across New York. Communities of color and low-income populations experience disproportionately higher rates of asthma and related complications. Data reveals that Black New Yorkers are over nine times more likely to require emergency department (ED) visits for asthma-related issues compared to their White counterparts, while Hispanic New Yorkers face a fourfold increased risk. Similarly, individuals residing in low-income zip codes are three times more likely to seek emergency care for asthma than those in wealthier areas.
These stark disparities highlight the intersection of asthma with broader social determinants of health, including economic hardship and environmental factors. Is it acceptable that where you live and your socioeconomic status can dramatically impact your ability to breathe freely?
Recent Progress and Remaining Challenges
Earlier this year, mounting pressure from the HELP committee and Senator Bernie Sanders prompted three major inhaler manufacturers – AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline – to agree to cap the price of their inhaler products at $35 or less per month. This price cap applies to individuals with commercial insurance and those who are uninsured, accessible through pharmacies or copay cards.
However, a significant gap remains. Individuals enrolled in government-funded healthcare programs like Medicare and Medicaid are excluded from this price reduction due to federal regulations. This leaves a vulnerable population – often those most in need – continuing to struggle with unaffordable medication costs.
New York Lawmakers Step Forward
Recognizing the urgency of the situation, New York State Assembly Member Jessica González-Rojas and State Senator Gustavo Rivera have proposed legislation to eliminate cost-sharing requirements for inhalers. The bill aims to ensure that inhalers are covered by insurance at no cost to the patient, removing financial barriers to access. Assembly Member González-Rojas’s district in Queens, and Senator Rivera’s in the Bronx, both experience high rates of asthma-related hospitalizations, underscoring the critical need for this legislation.
Several other states – Minnesota, Illinois, Washington, and New Jersey – have already enacted similar measures, capping inhaler cost-sharing at $25, $35, and $50 per month, respectively. Elisabeth R. Benjamin, Vice President of Health Initiatives at the Community Service Society of New York, aptly stated, “This smart bill will ensure that insurance cost-sharing is never a barrier to accessing life-sustaining inhalers for those who need it.”
What more can be done to ensure equitable access to asthma care for all New Yorkers?
Frequently Asked Questions About Asthma and Inhaler Costs
What is Asthma Peak Week and why does it occur in September?
Asthma Peak Week, typically occurring in the third week of September, is a period of increased asthma-related hospitalizations due to a combination of factors including peaking ragweed pollen levels, rising mold counts, the return to school and associated respiratory infections, and the beginning of flu season.
How much does an asthma inhaler typically cost in New York?
The cost of an asthma inhaler can vary, but it has drastically increased in recent years, potentially reaching up to $645 per month, according to the Senate Committee on Health, Education, Labor and Pensions (HELP).
Who is currently benefiting from the $35 inhaler price cap?
The $35 inhaler price cap currently applies to individuals with commercial insurance and those who are uninsured. It is accessible through local pharmacies or with a copay card.
Why are Medicare and Medicaid recipients excluded from the inhaler price cap?
Medicare and Medicaid recipients are excluded from the inhaler price cap due to existing federal restrictions.
What is the proposed legislation in New York State aiming to achieve?
The proposed legislation in New York State seeks to eliminate deductibles, copayments, and other cost-sharing requirements for inhalers, ensuring that they are covered by insurance at no cost to the patient.
Are there resources available to help individuals afford asthma medication?
Yes, several organizations offer assistance programs to help individuals afford asthma medication. You can explore options through the Asthma and Allergy Foundation of America (AAFA) and other patient advocacy groups. Asthma and Allergy Foundation of America
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
